Literature DB >> 4134298

Presence and possible role of anti-IgG antibodies in human malignancy.

D Hartmann, M G Lewis.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4134298     DOI: 10.1016/s0140-6736(74)90684-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  8 in total

1.  The relationship between cancer, radiotherapy and vitamin C.

Authors:  S C Kakar; C W Wilson; M J Moriarty
Journal:  Ir J Med Sci       Date:  1977-09       Impact factor: 1.568

2.  [Anti-immunoglobulins in multiple myeloma and benign monoclonal hyperglobulinemia].

Authors:  I Schedel; P C Fink; J Kalden
Journal:  Blut       Date:  1976-04

Review 3.  Tumour immunology and the gut.

Authors:  K C Calman
Journal:  Gut       Date:  1975-06       Impact factor: 23.059

4.  Circulating immune complexes in patients with lung cancer.

Authors:  J Lowe; A Segal-Eiras; P B Iles; R W Baldwin
Journal:  Thorax       Date:  1981-01       Impact factor: 9.139

5.  Interactions between IgM antiglobulins and IgG antinuclear antibodies. Some aspects of D-penicillamine activities.

Authors:  P S Mach; D Piatier; A Le Go; F Delbarre
Journal:  Clin Exp Immunol       Date:  1979-05       Impact factor: 4.330

6.  Circulating immune complexes in carcinoma of uterine cervix.

Authors:  P Seth; N Balachandran; A N Malaviya; R Kumar
Journal:  Clin Exp Immunol       Date:  1979-10       Impact factor: 4.330

7.  Host specificity of a serum marker for hepatitis B: evidence that "e antigen" has the properties of an immunoglobulin.

Authors:  A R Neurath; N Strick
Journal:  Proc Natl Acad Sci U S A       Date:  1977-04       Impact factor: 11.205

8.  Clinical relevance of circulating immune complexes in human leukemia. Association in acute leukemia of the presence of immune complexes with unfavorable prognosis.

Authors:  N A Carpentier; G T Lange; D M Fiere; G J Fournie; P H Lambert; P A Miescher
Journal:  J Clin Invest       Date:  1977-10       Impact factor: 14.808

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.